Read The Fine Print: China's New Data Protection Plan Has Some Catches
Executive Summary
China SDA's newest proposal gives six and 12 years' data protection for innovative new drugs and therapeutic biologics, respectively, but certain terms and conditions apply.
You may also be interested in...
Cancer, Orphan, Pediatric Drug Developers Join China Foreign Data Acceptance Party
China officially issues regulation accepting clinical data obtained from overseas studies, with a priority on treatments for critical, rare and pediatric conditions.
China Gene Therapy Developers Rush To Clinic In 'Winner Takes All' Battle
Gene therapies for conditions ranging from hemophilia to retinal diseases are blossoming in China and the race in which the winner may take all is on. Driven by ready investors, the field is on the cusp of becoming the latest innovation battleground in the country, while some developers are already moving ahead in the US.
Chinese Firms At JPM Not About China, It’s Time To Go Global
From BeiGene to Innovent to Wuxi Biologics, executives at Chinese pharma firms are now discussing collaborations to go beyond China to become biopharma operations with a truly global presence.